ENTRY       D10927                      Drug
NAME        Erdafitinib (JAN/USAN/INN);
            Balversa (TN)
PRODUCT     BALVERSA (Janssen Products LP)
FORMULA     C25H30N6O2
EXACT_MASS  446.243
MOL_WEIGHT  446.5447
CLASS       Antineoplastic
             DG01918  Tyrosine kinase inhibitor
              DG01917  Receptor tyrosine kinase inhibitor
               DG03208  FGFR inhibitor
            Metabolizing enzyme substrate
             DG01642  CYP2C9 substrate
             DG01633  CYP3A/CYP3A4 substrate
              DG02913  CYP3A4 substrate
            Transporter substrate
             DG01665  ABCB1 substrate
            Transporter inhibitor
             DG01622  ABCB1 inhibitor
             DG02863  SLC22A2 inhibitor
REMARK      ATC code: L01EN01
            Product: D10927<US>
EFFICACY    Antineoplastic, Receptor tyrosine kinase inhibitor
  DISEASE   Urothelial carcinoma (FGFR3 or FGFR2 genetic alterations) [DS:H00022]
COMMENT     Treatment of cancer
TARGET      FGFR3* (CD333) [HSA_VAR:2261v2] [HSA:2261] [KO:K05094]
            FGFR2* (CD332) [HSA_VAR:2263v2] [HSA:2263] [KO:K05093]
  PATHWAY   hsa04151(2260+2261+2263+2264)  PI3K-Akt signaling pathway
            hsa05200(2260+2261+2263+2264)  Pathways in cancer
            hsa05219(2261)  Bladder cancer
METABOLISM  Enzyme: CYP2C9 [HSA:1559], CYP3A4 [HSA:1576]
            Transporter: ABCB1 [HSA:5243]
INTERACTION Transporter inhibition: ABCB1 [HSA:5243], SLC22A2 [HSA:6582]
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L01 ANTINEOPLASTIC AGENTS
               L01E PROTEIN KINASE INHIBITORS
                L01EN Fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitors
                 L01EN01 Erdafitinib
                  D10927  Erdafitinib (JAN/USAN/INN) &lt;US&gt;
            USP drug classification [BR:br08302]
             Antineoplastics
              Molecular Target Inhibitors
               Erdafitinib
                D10927  Erdafitinib (JAN/USAN/INN)
            Drug groups [BR:br08330]
             Antineoplastic
              DG01918  Tyrosine kinase inhibitor
               DG01917  Receptor tyrosine kinase inhibitor
                DG03208  FGFR inhibitor
                 D10927  Erdafitinib
             Metabolizing enzyme substrate
              DG01642  CYP2C9 substrate
               D10927  Erdafitinib
              DG01633  CYP3A/CYP3A4 substrate
               DG02913  CYP3A4 substrate
                D10927  Erdafitinib
             Transporter substrate
              DG01665  ABCB1 substrate
               D10927  Erdafitinib
             Transporter inhibitor
              DG01622  ABCB1 inhibitor
               D10927  Erdafitinib
              DG02863  SLC22A2 inhibitor
               D10927  Erdafitinib
            Target-based classification of drugs [BR:br08310]
             Protein kinases
              Receptor tyrosine kinases (RTK)
               FGFR family
                FGFR2* (CD332) [HSA_VAR:2263v2]
                 D10927  Erdafitinib (JAN/USAN/INN) &lt;US&gt;
                FGFR3* (CD333) [HSA_VAR:2261v2]
                 D10927  Erdafitinib (JAN/USAN/INN) &lt;US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D10927
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D10927
            Drug metabolizing enzymes and transporters [br08309.html]
             Drug metabolizing enzymes
              D10927
             Drug transporters
              D10927
            Pharmacogenomic biomarkers [br08341.html]
             Somatic variations in targeted cancer therapies
              D10927
DBLINKS     CAS: 1346242-81-6
            PubChem: 342581784
            PDB-CCD: 5SF
ATOM        33
            1   C8y C     9.7300  -15.3300
            2   C8y C     9.7300  -16.7300
            3   C8x C    10.9200  -17.4300
            4   C8x C    12.1800  -16.7300
            5   C8y C    12.1800  -15.3300
            6   C8x C    10.9200  -14.6300
            7   N5x N     8.5400  -14.6300
            8   C8y C     7.2800  -15.3300
            9   C8x C     7.2800  -16.7300
            10  N5x N     8.5400  -17.4300
            11  C8y C     6.0900  -14.6300
            12  C8x C     5.9500  -13.2300
            13  N5x N     4.5500  -12.9500
            14  N4y N     3.8500  -14.1400
            15  C8x C     4.8300  -15.1900
            16  C1a C     2.4500  -14.2800
            17  N1c N    13.3700  -14.6300
            18  C1b C    14.6300  -15.3300
            19  C1b C    15.8200  -14.6300
            20  N1b N    17.0100  -15.3300
            21  C1c C    18.2700  -14.6300
            22  C1a C    19.4600  -15.3300
            23  C8y C    13.3700  -13.2300
            24  C8y C    12.1800  -11.1300
            25  C8x C    12.1800  -12.5300
            26  C8x C    14.6300  -12.5300
            27  C8y C    14.6300  -11.1300
            28  C8x C    13.3700  -10.4300
            29  O2a O    10.9647  -10.4349
            30  O2a O    15.8366  -10.4200
            31  C1a C    17.0463  -11.1053
            32  C1a C     9.7763  -11.1277
            33  C1a C    18.2872  -13.2301
BOND        36
            1     1   2 2
            2     2   3 1
            3     3   4 2
            4     4   5 1
            5     5   6 2
            6     1   6 1
            7     1   7 1
            8     7   8 2
            9     8   9 1
            10    9  10 2
            11    2  10 1
            12    8  11 1
            13   11  12 1
            14   12  13 2
            15   13  14 1
            16   14  15 1
            17   11  15 2
            18   14  16 1
            19    5  17 1
            20   17  18 1
            21   18  19 1
            22   19  20 1
            23   20  21 1
            24   21  22 1
            25   17  23 1
            26   24  25 2
            27   25  23 1
            28   26  27 1
            29   27  28 2
            30   24  28 1
            31   26  23 2
            32   24  29 1
            33   27  30 1
            34   30  31 1
            35   29  32 1
            36   21  33 1
///
